Christina A.M. Jamieson, PhD

Biography: Christina Jamieson, PhD, is an Associate Professor of Urology at the University of California, San Diego (UCSD) Medical School and Moores Cancer Center. Dr. Jamieson received her PhD in Molecular Immunology in the laboratory of Dr. Ranjan Sen at Brandeis University, Waltham, MA. Dr. Jamieson moved to the University of California, San Francisco (UCSF) for her postdoctoral fellowship first with Dr. Dan R. Littman 1993-1994, then Dr. Keith R. Yamamoto from 1995-2000. She was promoted to Advanced Health Sciences Researcher in 2001 at UCSF then to Assistant Professor, UC, Los Angeles (UCLA), Dept of Human Genetics and Urology in 2002. Dr. Jamieson became an Assistant Professor at UC, San Diego (UCSD), Dept of Surgery/Div. Urology in 2011, and was promoted to Associate Professor, UCSD Urology in 2015. Dr. Jamieson has focused on bone metastatic prostate cancer and urologic immune-oncology. Dr. Jamieson has been continuously funded by significant philanthropic and a range of grant funding agencies as well as industry for testing novel therapies and immunotherapies for bone metastatic prostate cancer. Dr. Jamieson is currently PI of a DoD PCRP Impact Award, Co-PI on two Padres Pedal the Cause Translational Research/Clinical trials grants and is the translational scientist on four clinical trials. Dr. Jamieson has served on multiple scientific review panels for the Department of Defense and Prostate Cancer Foundation. She is on the Editorial Board of Scientific Reports and reviews for a broad range of basic science journals. Dr. Jamieson first joined the SBUR in 2003, became a full member in 2010, was the recipient of a SBUR Travel Award in 2014 and participated on the SBUR 2019 Fall Symposium Planning Committee. She gave three oral presentations and Co-Chaired several sessions of SBUR Spring and Fall Symposia and is serving as SBUR By-Laws Committee President.

Research Interests: Dr. Jamieson's research focuses on metastatic prostate cancer and ureter tract cancers. My goal is to develop and test new molecularly targeted therapies and immunotherapies to eradicate these lethal diseases. The central tenet of my approach is to study and use patient specimens to generate new models and use them to perform pre-clinical studies for novel treatments as well as to advance understanding of disease mechanisms of resistance. These patient-derived models more accurately replicate and retain the features of the disease tissues, and thus, are more predictive of patient disease responses when used to test therapies. This translational research is made possible by the close collaboration with the clinical team of urologists, orthopedic surgeon and urologic oncologists. We established a biobank of patient prostate cancer bone metastases, a new series of patient-derived xenografts (PDX) and 3D *in vitro* patient-derived organoid (PDO) model systems for testing new therapies in cells from prostate cancer bone metastases. The **PCSD (Prostate Cancer San Diego)** *in vivo* PDX and PDO models closely recapitulate the bone metastatic disease seen in patients. These models are available for collaboration with the research community. We are using them to develop novel therapies including immunotherapies such as CART and NK cell immunotherapies. My group was the first to show that the bone microenvironment itself supports castration resistant growth of bone metastatic prostate cancer (CRPC). We have identified gene networks associated with prostate cancer growth in the bone which we are investigating in organoids. We recently established patient-derived organoids with autologous tumor infiltrating T cells (TILs) to investigate immune-oncology mechanisms and therapies.

Vision Statement: As longa member of SBUR for 17 years, I have benefitted immensely from the outstanding research presentations and the collaborative and supportive camaraderie unique to the SBUR. I am deeply and enthusiastically committed to spreading these benefits to the greater Urology research community. If I have the honor of being elected Secretary I plan to help:

1) Enhance communication within the SBUR membership The heart of the SBUR and the job of the Secretary is to ensure and enhance communication between members of the urology research community. In 2020, a year like no other, we had to adapt and to improve our remote communication tools. I would help expand on the innovative adaptations necessitated by the COVID-19 pandemic that the SBUR accomplished this year via the successful Virtual Symposia. I will work to ensure the continuation and increase in scientific communication in the SBUR. I will work to expand on innovative communication platforms and opportunities, for example, host Quarterly Zoom meetings to discuss potential collaborations on grants and projects, especially to foster inter-disciplinary research. I would actively work on innovative ways to expand on the benefits and ease of participation in virtual meetings and exciting new ways to share information and ideas online. I would help plan new approaches for future meetings such as permanently maintaining some virtual facets as we eventually go back to in-person meetings.

2) Promote maintenance and expansion of SBUR membership list, enhance retention of current members, reach out to past members: I plan to work closely with the Membership committee to ensure we effectively communicate to attract and retain members from our trainees, clinicians and scientists interested in urology research to allow the SBUR to thrive as an essential and valued resource and community for urology research.

CHRISTINA A.M. JAMIESON, Ph.D.
Associate Professor of Urology,
Department of Urology, Division of Urologic Oncology
Member, Moores Cancer Center
University of California, San Diego School of Medicine

OFFICE ADDRESS:

UC San Diego Moores Cancer Center, Room 4326
3855 Health Sciences Drive #0820
La Jolla, CA 92093-0820
Phone: (858) 534-2921
FAX: (858) 822-6288
Email: CAMJamieson@ucsd.edu

EDUCATION:

Degree-Granting Education

University of British Columbia, Vancouver, Canada BSc, Honors, Microbiology and Immunology

Brandeis University, Waltham, MA, Ph.D., Molecular Immunology

Postgraduate Training

Graduate Student, Dept. of Biology, Brandeis University, Waltham, MA, Doctoral Thesis: NF–κB: Physiologic Activation, Function and Associating Proteins. Advisor: Ranjan Sen, Ph.D., 1986-1992

Postdoctoral Fellow, University of California, San Francisco (UCSF), Dept. of Immunology, Advisor: Dr. Daniel R. Littman, M.D., Ph.D., Effect of the HIV coat protein, gp120, on T cell development and function in hCD4 mice. Generation of ES cells homozygous for targeted disruption of the transcription factor, HEB, in mice. 1993-1995

Postdoctoral Fellow, University of California, San Francisco (UCSF), Dept. of Cellular and Molecular Pharmacology, Advisor: Keith R. Yamamoto, Ph.D., Identified MEK1/2 as the crosstalk signal from the T cell receptor necessary and sufficient to protect against glucocorticoid-mediated apoptosis, 1995-1998

Senior Postdoctoral Fellow, University of California, San Francisco (UCSF), Dept. of Cellular and Molecular Pharmacology Advisor: Keith R. Yamamoto, Ph.D., Mechanisms of signaling crosstalk in the function of steroid hormone receptors GR and AR function. 1998 -1999

Advanced Health Sciences Researcher, University of California, San Francisco (UCSF), Faculty Mentors: Keith R. Yamamoto, PhD and Rik Derynck, PhD. Mouse microarray gene expression profiling of glucocorticoid-induced apoptosis in T cells, 2000-2002

Director and Founder, University of California, San Francisco (UCSF), Custom microarray consortium, Developed, made and used whole mouse and human genome DNA microarrays, 2000 -2002

EXPERIENCE/SERVICE

Academic Appointments

Associate Professor, Dept. of Urology, School of Medicine, University of California, San Diego (UCSD), 2015-present.

Assistant Professor, Dept. of Surgery/ Urology, School of Medicine, University of California, San Diego (UCSD), 2011-2015.

Assistant Professor, Dept. of Urology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 2002-2010

Assistant Professor, Dept. of Human Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 2002-2010

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Dept. of Urology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 2002-2010

Assistant Professor, Dept. of Human Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA), 2002-2010

Academic Administrative Appointments/Responsibilities

Director and Founder, UCLA Custom Microarray Consortium (CMC), 2003 –2010

UCSD Urology Fellow and Resident Interviewer

Institutional Committee Activities

Human Genetics Seminar Speakers Committee, Dept. of Human Genetics, UCLA, 2002-2010

Microarray Users Group (MUG), Leader and founder: Group of 12 labs sharing resources to produce, use and analyze DNA microarrays, UCLA, 2003-2010

Custom Microarray Printing Committee, Chair, 2003-2010

Ataxia telangiectasia, ATM and Cancer Research Group, Depts of Human Genetics and Pathology, UCLA, 2003-2007

Committee on Diversity, UCLA 2009-2010

Dept. of Surgery Annual Research Symposium Organizing Committee, UCSD 2011, 2012, 2013, 2014

Elected Member of the Representative Assembly of the UCSD Academic Senate, 2017, 2018, 2019

UCSD Dept of Urology Annual Research Symposium, Organizer and Co-Chair, Sept 2017 - present

Member, UCSD Institutional Animal Care and Use Committee (**IACUC**), 2018-2021

Urology Chair Search Committee, 2018-2019

UCSD GenitoUrinary (GU) Translational Research Group, 2018-present

Co-Chair, Immuno-oncology Interest Group (**iOiG**), formerly the San Diego Center for Precision Immunology (SDCPI) committee, now expanded to include Moores Cancer Center members (CCSG) and SDCPI, June 2020 -present

Co-Chair and moderator, Moores Cancer Center Solid Tumor Therapy (STT) Annual Retreat Virtual Conference, Sept 18th, 2020

HONORS and AWARDS

Career Development Scholarship- Government of Canada & University of British Columbia, 1984

BSc. Honors - University of British Columbia, 1985

University of British Columbia Achievement Scholarship, 1985-1986

Brandeis University Graduate Student Fellowship, 1986-1992

National Cancer Institute of Canada Postdoctoral Fellowship (*declined*), 1992-1994

Medical Research Council of Canada Postdoctoral Fellowship (*declined*), 1992-1994

Damon Runyon-Walter Winchell Cancer Research Fund Postdoctoral Fellowship, 1993-1996

Medical Research Council of Canada Postdoctoral Fellowship, 06/96-06/97

Herbert Boyer Postdoctoral Fellowship, 01/96-06/96

American Heart Association Senior Fellowship (*declined*), 07/97-07/98

American Cancer Society, California Div. Senior Postdoctoral Fellowship (*declined*), 07/97-07/99

Arthritis Foundation Senior Postdoctoral Fellowship, 07/97-07/00

Outstanding Poster Award - Gordon Research Conference: Hormone Action1999, 07/99

Herbert Boyer Postdoctoral Fellowship, 07/00-01/01

UCSF Sandler Program in Basic Sciences: New Technology Resources Awards, 02/01-02/03

New Investigator Award: Gordon Research Conference: Mechanisms of Hormone Action, 08/03

UCLA Faculty Research Award, (FRG), 2006

Abstract Selected for Oral Presentation, AUA Annual Conference, Washington, DC, 2011

Abstract Selected for Oral Presentation, AUA Annual Conference, Atlanta, GA, 2012

Abstract Selected for Oral Presentation, AUA Annual Conference, Orlando, FL, 2014

Plenary Speaker, 2014 South Taihu Lake International Symposium on Cancer Therapy and Nursing Sciences, Huzhou City, Zhejiang Province, China June 28-30, 2014.

Travel Award Winner and Speaker, 2014 Society for Basic Urologic Research Fall Symposium

11/2014 , Nashville TN

Winner Best Moderate Poster and Oral Presentation, Session MP61: Prostate Cancer: Basic Research, AUA Annual Meeting, 5/2015, New Orleans, LA

UCSD Undergraduate Scientific Best Mentor Award BSP program, Nominating Mentee Theresa Mendoza 2015

Participant at the Invitation-only Prostate Cancer Foundation (PCF) 2016 Coffey-Holden Prostate Cancer Academy Meeting "Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer", June 23-26, 2016, Coronado Bay, San Diego, CA

Winner Best Moderate Poster and Oral Presentation, Session MP87: Prostate Cancer: Basic Research, AUA Annual Meeting, May 12-16, 2017, Boston, MA

Participant at the Invitation-only Prostate Cancer Foundation (PCF) 2016 Coffey-Holden Prostate Cancer Academy Meeting "Beyond the Androgen Receptor II: New Approaches to Understanding and Treating Metastatic Prostate Cancer ", June 14-17, 2017, Carlsbad, San Diego, CA

Nominee, Director-At Large, Society for Basic Urologic Research (SBUR), 1/2018

Chair, Bylaws Committee, Society for Basic Urologic Research (SBUR), 3/2018

Member, SBUR Annual Meeting Committee, 2018-2019

Nominee, Executive Committee, Secretary, Society for Basic Urologic Research (SBUR), 2021-2023

RESEARCH

RESEARCH GRANTS AND CONTRACTS AWARDED:

ACTIVE

Jamieson 09/01/2020-08/31/2021
Sanford Stem Cell Clinical Center Annual: $50,000
2020 Special Call for COVID-19 Projects
Inhibition of SARS-CoV2 by transcriptional repression of the host viral entry co-factor, TMPRSS2.
Project Goals/Aims: Investigate the hypothesis that downregulation of the COVID-19 viral entry host factor, TMPRSS2, will reduce viral infection. Develop and use 3D organoid models from patient-derived tissues to test drugs including androgen signal inhibitors that inhibit TMPRSS2 expression.
Role: PI Effort: 8%

Jamieson 09/01/2020-08/31/2021
Oncternal Therapeutics, Inc. Annual: $104,902
Laboratory Service Agreement (LSA)
Testing Oncternal Therapeutics drugs in PDX and PDO models for metastatic prostate cancer
Project Goals/Aims: Investigate the hypothesis that novel drugs will show efficacy in patient derived organoid and xenograft models of metastatic prostate cancer that predicts response in patients.
Role: PI Effort: 10%

Miranti 05/01/2020-04/30/2021 .6 Cal Mo
American Cancer Society Annual: $32,400 Entire Period: $64,800

Targeting Bone Metastatic Castration Resistant Prostate Cancer
Project Goals/Aims: Investigating the therapeutic targeting of the survival pathways that confer resistance to ADT and PI3K inhibition in CRPC
Role: Co-I Effort: 5%

Parsons 01/01/2020-12/31/2021
Padres Pedal the Cause Annual: $150,000 Entire Period: $300,000
A Phase 1B, Nonrandomized Trial Investigating Docetaxel Combined with Cirmtuzumab in Patients with Metastatic Castration Resistant Prostate Cancer.
Project Goals/Aims: Investigating the hypotheses that cirmtuzumab combined with standard of care docetaxel will be 1) tolerable and safe, 2) result in early antitumor activity in patients with treatment-refractory CRPC, and 3) may demonstrate a signal of enhanced efficacy in patients with WSP activation in the context of a phase Ib trial of cirmtuzumab combined with docetaxel in patients with metastatic CRPC.
Role: Co-I Effort: N/A

Jamieson W81XWH-19-1-0672 09/30/2019-09/29/2022 4 Cal Mo
Department of Defense Annual: $365,389 Entire Period: $1,096,167
Targeting WNT5A-mediated Therapy Resistance Mechanisms and tumor genomic heterogeneity in Lethal Bone Metastatic Prostate Cancer.
2018 Department of Defense CDMRP PCRP IMPACT Award PC180705
Clinical Co-I: Christopher J Kane, MD
Project Goals/Aims: Investigating the role of WNT5A and ROR1 and therapeutic targeting in bone metastatic prostate cancer and preparation for Phase 1 clinical trial.
Role: PI Effort: 18%

Jamieson 01/01/2019-12/31/2021
Investigating the Efficacy of radium-223 with Olaparib in Men with Metastatic Castration-resistant Prostate Cancer.
Padres Pedal the Cause Annual: $150,000 Entire Period: $300,000
Project Goals/Aims: Investigating the hypothesis that the combination of radium-223 and olaparib will result in improved outcomes (radiographic progression-free survival) in mCRPC patients. in the context of a National Cancer Institute (NCI) phase I/II randomized clinical trial of radium-223 with or without olaparib.
Role: Co-PI Effort: 8%

Jamieson 05/01/2018 – 4/30/2020
JM Foundation Annual: $250,000 Entire Period: $500,000
New Patient-derived Models of Bone Metastatic Prostate Cancer.
To determine the properties of tumor initiating cancer stem cells in the Prostate Cancer San Diego (PCSD) cohort of banked patient bone metastatic prostate cancer samples and patient derived xenografts.
Project Goals/Aims: Developing Cancer Stem Cell targeting therapies in bone metastatic Prostate Cancer
Role: PI

Jamieson 10/01/2016 – 10/31/2019 (NCE)
Leo and Anne Albert Charitable Foundation Annual: $150,000 Entire Period: $450,000

New Patient-derived Models of Bone Metastatic Prostate Cancer
To elucidate the support signals that the bone niche provides for prostate cancer and develop new therapies.
Project Goals/Aims: Developing and Using new patient derived models of bone metastatic prostate cancer for testing therapies.
Role: PI

Jamieson
Leo and Anne Albert Charitable Foundation 10/2016 – 10/2019, 3.6 Calendar Months, 30% effort

Renewed New Patient-derived Models of Bone Metastatic Prostate Cancer
Total $450,000; $150,000 awarded per year

Parsons 09/01/2014 – 08/31/2020
NIH NCI
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance. DCP Protocol #: UAZ2014-03-01
Project Goals/Aims: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells that express PSA.
NIH NCI DCP Protocol #: UAZ2014-03-01, Local Protocol #: Pending Consortium Name: The University of ArizonaEarly Phase Cancer Prevention Consortium, Consortium Principal: H-H Sherry Chow, PhD, Protocol Principal Investigator & Site Leader: J Kellogg Parsons, MD, MHS
1.2 Calendar Months
Award to Jamieson, UCSD sub-award**: $71,820**
Role: Co-I

Heemers 09/01/2016– 11/30/2020
Dept. of Defense
FY15 Prostate Cancer Research Program Idea Development Award
The control by PKN1 and CIT over SRF-dependent androgen action as a target for selective and CaP- specific ADT.
Project Goals: Analysis of SRF-dependent pathways in CRCP in PDX models.
Role: Co-I

PENDING

Jamieson Total for Jamieson: $750,000 05/01/2021-04/30/2024
2020 Dept of Defense CDMRP PCRP IDEA Award
Advancing Cirmtuzumab-based anti-ROR1 CAR-T cells to eradicate lethal castration resistant prostate cancer.
Role: Co-PI Effort: 20%

Garabedian, M (NYU) Total for Jamieson: $48,000 05/01/2021-04/30/2024
2020 Dept of Defense CDMRP PCRP IDEA Award
Peptoid conjugates that block androgen receptor activity and promote anti-tumor immunity in therapy resistant prostate cancer.
Role: Co-I Effort: 20%

Jamieson/Kaufmann Total for Jamieson: $104,000 05/01/2021-04/30/2022
NIH STTR
First-in-class inhibitor targeting ETS proteins and TMPRSS2-ETS gene fusions for treatment of prostate cancer
Role: Academic PI with Oncternal Therapeutics, Inc.

Garabedian, M (NYU) Total for Jamieson: $361,146 04/01/2021-03/31/2026
2020 NIH RO1
Peptoid conjugates that block androgen receptor activity and promote anti-tumor immunity in prostate cancer
Role: Co-I Effort: 5%
Sanghee Lee effort: 10% (2 calendar months)

Mckay, R, Jamieson, C (UCSD) Total for Jamieson: $148,266 11/1/2020-10/31/2022
2020 Prostate Cancer Foundation Challenge Award
Therapeutic targeting of noncanonical Wnt signaling in advanced castration resistant prostate cancer.
Role: Co-PI Effort: 5%
Sanghee Lee effort: 5%

Heemers, H (Cleveland Clinic) Total for Jamieson: $133,402 11/1/2020-10/31/2022
2020 Prostate Cancer Foundation Challenge Award
Citron kinase inhibition to overcome prostate cancer treatment resistance
Role: Co-I Effort: 10%
Sanghee Lee effort: 16.7% (2 calendar months)

Stoyanova, T (Stanford Univ) Total for Jamieson: $100,000 11/1/2020-10/31/2022
2020 Prostate Cancer Foundation Challenge Award
Novel Glycolytic Inhibitor for Treatment of Advanced Prostate Cancer
Role: Co-I Effort: 5%
Sanghee Lee effort: 5%

Kaufmann, G, (Oncternal Therapeutics, Inc, San Diego) Total $ 170,476 01/01/2021-12/31/2022
2020 NIH SBIR
Oral Formulation Development and Indication Expansion for First-in-class ETS inhibitor TK216 for Treatment of Solid Tumors and Hematological Malignancies
Role: Co-PI Effort: 20%
Sanghee Lee effort: 16.7% (2 calendar months)

Jamieson
LSA Oncternal Therapeutics, Inc. Total: $104,902 8/1/2020-7/31-2022
Testing Oncternal Therapeutics, Inc. drugs in pre-clinical models of metastatic prostate cancer.
Role: PI Effort: 10%
Sanghee Lee effort: 16.7% (2 calendar months)

Jamieson
LSA Vividion Therapeutics, Inc.
Testing Vividion Therapeutics, Inc. drugs in pre-clinical models of metastatic prostate cancer.
Role: PI Effort: 10%
Sanghee Lee Effort: 20%

Stoyanova
NIH NCI 01/01/2021-12/31/2024
Developing new therapies for advanced prostate cancer
Project Goals: To test the therapeutic potential of SU086 on bone metastasis of prostate cancer a potent inhibitor, SU086, of prostate cancer growth in vitro and in vivo that impairs glycolysis in prostate cancer.
Role: Co-I Effort: 5%
Sanghee Lee % effort: 10%

Karin
Dept of Defense CDMRP PCRP IDEA award 09/01/2020-8/31/2023
PC190303 DoD Idea Award FY19
Title: Identifying histone acetyl transferase activation for immunotherapy of treatment-refractory and metastatic prostate cancer
Project Goals: Analysis of immunotherapy to counteract mechanisms of chemotherapy resistance in prostate cancer
Role: Co-I Effort: 5%

APPLIED FOR, NOT FUNDED

Jamieson, Co-Investigator 02/01/2019-01/31/2021 $150,000 UCSD Sub-Award

Biomimetic nanoparticles made from iPS cell derived mesenchymal stem cells for targeted therapy of metastatic prostate cancer
2018 Department of Defense CDMRP PCRP IDEA Award Selected, Full Application
PI: Fei Liu, MD, PhD, Texas A&M University Health Science Center

Jamieson, Principal Investigator 12/01/2018-11/30/2020 $978,931
Targeting WNT5A-mediated Therapy Resistance Mechanisms and tumor genomic heterogeneity in Lethal Bone Metastatic Prostate Cancer.
2018 Prostate Cancer Foundation Challenge Award
Clinical Co-I: Christopher J Kane, MD

Jamieson, Co-Investigator 09/01/2018-08/31/2019 $100,000
Therapeutic Targeting of the survival pathways that confer resistance to ADT and PI3K inhibition in CRPC
American Cancer Society (ACS) Mission Boost grant
PI Cindy Miranti, Univ.of Arizona, Tucson

Jamieson, Principal Investigator 06/01/2018-05/31/2019 $50,000
Single cell analysis of heterogeneity and androgen deprivation therapy (ADT) resistance in bone metastatic prostate cancer.
Moores Cancer Center Translational and Clinical Cancer Research Awards
Clinical PI: Christopher J Kane, MD

Jamieson, Principal Investigator 06/01/2018-05/31/2019 $40,000
Single cell RNA sequencing of twenty surgical patient prostate cancer bone metastases.
Academic Senate Health Sciences Research Grant Committee Research/Bridge Grant Application

Jamieson, Principal Investigator, 07/01/2018– 06/30/2019 $125,000
Small Molecule Inhibitors of the Autophagy Initiating Kinase, ULK1, for the Treatment of Castrate Resistant Prostate Cancer.
Padres Pedal the Cause/ San Diego NCI Cancer Centers Council (C3) 2018 application for collaborative translational cancer research pilot project.
With Co-PIs: Nicholas Cosford, PhD, Sanford Burnham Prebys and Christopher Kane, MD, Moores Cancer Center

Jamieson, Co- Investigator, 09/01/2018– 8/31/2021 $1,300,000
NIH NCI,
Therapeutic Targeting of the survival pathways that confer resistance to ADT and PI3K inhibition in CRPC
PI: C. Miranti, University of Arizona, Tucson

Jamieson, Co- Investigator, 09/01/2018– 8/31/2021 $300,000
NIH NCI,
Therapeutic Treatment of resistant prostate cancer with beta-catenin inhibitors
PI: Susan Logan, New York University, New York
Jamieson, Co-Investigator 03/01/2018– 2/28/2021 $87,109
TRAN1, California Institute of Regenerative Medicine (CIRM)
Novel CAR-T cell immunotherapy for prostate cancer, PI: Eric Ostertag, Poseida

Jamieson, Partnering Principal Investigator, 09/01/2018– 8/31/2021 $1,162,500
Dept of Defense Impact Award,
Therapeutic Targeting of the Bone Microenvironment to Overcome PI3K Resistance in CRPC
PI: C. Miranti, University of Arizona, Tucson

Jamieson, Co-Investigator, 09/01/2018– 8/31/2021 UCSD Sub award: $77,418

Dept. of Defense IDEA Award
LINE-1 in prostate cancer
PI: Susan Logan, New York University, New York

Jamieson, Co-Investigator, 09/01/2018– 8/31/2021 UCSD Sub award: $77,418
Dept. of Defense IDEA Award
Treatment of resistant prostate cancer with beta-catenin inhibitors
PI: Susan Logan, New York University, New York

Jamieson, Principal Investigator 01/01/2018– 12/31/2019 $50,000
Moores Cancer Center Pilot Project
Developing a Red/Far-Red optogenetic on/off switch system for localized treatment of pain in bone metastatic prostate cancer using patient-derived 3D organoids and xenografts

Jamieson, Principal Investigator 01/01/2018– 12/31/2019 $50,000
Moores Cancer Center Pilot Project
High resolution bladder electromyography (HR-BEMG) for monitoring post-prostatectomy bladder function recovery Non-invasively

Jamieson, Co- Investigator, 09/01/2018– 8/31/2021
NIH NCI,
Therapeutic Targeting of the survival pathways that confer resistance to ADT and PI3K inhibition in CRPC
PI: C. Miranti, University of Arizona, Tucson $1,300,000

Jamieson, Co- Investigator, 09/01/2018– 8/31/2021
NIH NCI,
Therapeutic Treatment of resistant prostate cancer with beta-catenin inhibitors
PI: Susan Logan, New York University, New York $300,000

Jamieson Co-Investigator 03/01/2018– 2/28/2021
TRAN1, California Institute of Regenerative Medicine (CIRM)
Novel CAR-T cell immunotherapy for prostate cancer
PI: Eric Ostertag, Poseida $87,109

Jamieson Partnering Principal Investigator, 09/01/2018– 8/31/2021
Dept of Defense Impact Award,
Therapeutic Targeting of the Bone Microenvironment to Overcome PI3K Resistance in CRPC
PI: C. Miranti, University of Arizona, Tucson $1,162,500

Jamieson Co-Investigator, 09/01/2018– 8/31/201
Dept. of Defense IDEA Award
LINE-1 in prostate cancer
PI: Susan Logan, New York University, New York $77,418

Jamieson Co-Investigator, 09/01/2018– 8/31/201
Dept. of Defense IDEA Award
Treatment of resistant prostate cancer with beta-catenin inhibitors
PI: Susan Logan, New York University, New York $77,418

Jamieson Principal Investigator
Moores Cancer Center Pilot Project
Developing a Red/Far-Red optogenetic on/off switch system for localized treatment of pain in bone metastatic prostate

cancer using patient-derived 3D organoids and xenografts $50,000

Jamieson, Principal Investigator 01/01/2018– 12/31/2019
Moores Cancer Center Pilot Project
High resolution bladder electromyography (HR-BEMG) for monitoring post-prostatectomy bladder function recovery Non-invasively. $50,000

Jamieson, Principal Investigator, 09/01/2017– 08/31/2018
Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone.
Thermofisher Tumor Profiling Grant Genomics Services and reagents: $65,000

COMPLETED

Howell, Kane
Jamieson, Co-Investigator, ML28615 **-** A Phase II Study of Rituximab Neoadjuvant Therapy in Patients with High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy, **ClinicalTrials.gov Identifier:** NCT01804712 **Roche-**Genentech, Inc. PI: S. Howell, Total Award: $267,265; Award for C. Jamieson, no salary:
$42,000

Jamieson, Principal Investigator, 1st (Feb 27-28, 2015) and 2nd (Feb 2017) Leo and Anne Albert Symposium on Current Therapy and Future Directions in Bone Metastatic Prostate Cancer: from Palliation to Cure. Chair and Program Director, Leo and Anne Albert Charitable Foundation 10/2018 – 10/2019
$120,000

Jamieson, Principal Investigator, Three summer interns research funding New Patient-derived Models of Bone Metastatic Prostate Cancer
Leo and Anne Albert Charitable Foundation 06/01/2018 – 09/21/2018,
$16,500

Jamieson, Principal Investigator,11/01/15-10/31/18
Testing Bispecific antibody for targeting CTLs cell immunotherapy in PDX models
California Institute for Biomedical Research (CaliBR) Study 1: $46,000
Study 2 funding approved and invoiced: $62,891
Total: $108,891

Jamieson, Principal Investigator,
Capella Therapeutics, Inc. 07/01/2015-06/30/2017,
Inhibition of Mutants of Epidermal Growth Factor Receptor Kinase for treatment of NSCLC and its Brain Metastases, Anticancer research at Capella Therapeutics Inc. The goal of this research is to find a therapeutic agent to treat NSCLC and its brain metastases driven by EGFR mutants. $40,000
Additional gift: $16,000
Total: $56,000

Jamieson, Principal Investigator, 12/01/15-11/30/18
Investigator Initiated Pre-Clinical Study: ENZA-15F06-UCSD-Jamieson
Testing enzalutamide in new patient derived xenograft models for bone metastatic prostate cancer.
Astellas/Medivation, Inc.
$75,053

Jamieson, Principal Investigator, 12/01/15-11/30/18
Testing Pfizer drugs in PDX model of bone metastatic prostate cancer.

Pfizer, Inc.
$100,000

Heemers
Jamieson, Co-investigator, 09/01/2016– 11/30/2019
The control by PKN1 and CIT over SRF-dependent androgen action as a target for selective and CaP-specific ADT.
Dept. of Defense FY15 Prostate Cancer Research Program (PCRP) Idea Development Award (IDA)
Program PI: Hannelore Heemers, 1.2 Calendar Months
$9,500.

Nguyen
Jamieson, Co-Investigator, Testing Fluorescently Labeled Probes for Nerve Imaging During Surgery
NIH - NIBIB 1R01EB014929 - 01A1, 08/08/2012 – 07/31/2016, 0.6 Calendar, PI: Quyen Nguyen, $225,000 (Annual, direct)
Total Award: $1,395,000, $52,700 (sub-award)

Jamieson, Principal Investigator, Testing AMBRX reagents in models for bone metastatic prostate cancer.
AMBRX, 08/01/13-07/31/15 $60,000

Karin,
Jamieson, Co-Investigator Inhibition of B cell Recruitment and CXCL13/CXCR5 Signaling in Prostate Cancer
Pfizer Centers for Therapeutic Innovation Pfizer CTI (PI: Michael Karin) 10/5/12 – 10/4/14
The goal was to determine the utility of CXCR5 blockade in castrate-resistant prostate cancer.

Jamieson, Principal Investigator (PI), Bone-niche and Castration-resistant Prostate Cancer
Phi Beta Psi Charity Trust (Jamieson CAM, Kane CJ) 8/15/12 – 8/14/14
The goals were to develop novel *in vivo* and *in vitro* models for castration-resistant prostate cancer in the bone niche using primary prostate cancers and bone metastases to identify biomarkers and targets for molecular therapy.

CLINICAL TRIALS

Co-Investigator, ML28615 **-** A Phase II Study of Rituximab Neoadjuvant Therapy in Patients with High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy, **ClinicalTrials.gov Identifier:** NCT01804712 **Roche-Genentech, Inc.** PI: S. Howell, Total Award: $267,265; Award for C. Jamieson, no salary:

Co-Investigator, Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance. NIH NCI DCP Protocol #: UAZ2014-03-01, Local Protocol #: Pending Consortium Name: The University of Arizona Early Phase Cancer Prevention Consortium, Consortium Principal: H-H Sherry Chow, PhD, Protocol Principal Investigator & Site Leader: J Kellogg Parsons, MD, MHS

Co-Investigator, Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone. NCT: NCT03317392, UCSD Site PI: Dr. Rana Mckay

Co-Investigator, A Phase 1B, Nonrandomized Trial Investigating Docetaxel Combined with Cirmtuzumab in Patients with Metastatic Castration Resistant Prostate Cancer. PI: Dr. J. Kellog Parsons, UCSD, Co-Investigator: Dr. Rana Mckay.

BIBLIOGRAPHY

Peer-Reviewed Publications

1. **Jamieson, C**, Mauxion, F, Sen, R. 1989. Identification of a functional binding site in the murine T cell receptor β locus. Journal of Experimental Medicine 170: 1737-1743.

2. **Jamieson, C** and Sen, R. 1990. The Methylation Interference Assay**.** DNA and Protein Engineering Techniques. 2: 73-88.

3. Mauxion, F, **Jamieson, C**, Yoshida, M, Arai, K-I, Sen, R. 1991. Comparison of constitutive and inducible transcription enhancement mediated by κB-related sequences: Modulation of activity in B cells by human T cell leukemia virus type 1 tax gene**.** Proceedings of the National Academy of Sciences 88: 2141-2145.

4. **Jamieson, C**, McCaffrey, PG, Rao, A, Sen, R. 1991. Physiologic Activation of T cells via the T cell antigen receptor induces NF-κB**.** Journal of Immunology 147: 416-420.

5. Wuerffel, R., **Jamieson, C**, Morgan, L, Merkulov, GV, Sen, R, Kenter, AL. 1992. Switch recombination breakpoints are strictly correlated with DNA recognition motifs for immunoglobulin Sγ3 DNA binding proteins. Journal of Experimental Medicine176: 339-49.

6. McCaffrey, PG, Jain, J, **Jamieson, C,** Sen, R, Rao, A. 1992. A T nuclear cell factor resembling NF-AT binds to an NF-κB sequence "Cytokine-1". JBiolChem 267:1864-1872.

7. Kenter, AL, Wuerffel, R, Sen, R, **Jamieson, C**, Merkulov, GV. 1993. Switch recombination breakpoints occur at nonrandom position in Sγ3 tandem repea**t.** Journal of Immunology.151: 4718-4731.

8. Pierce, JW, **Jamieson, CA**, Ross, JL, Sen, R. 1995. Activation of IL-2 receptor alpha-chain gene by individual rel oncogene family in association with serum response factor. Journal of Immunology 155: 1972-1980.

9. **Jamieson, CA** and Yamamoto, K.R. 2000. Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proceedings of the National Academy of Sciences. 97: 7319-7324.

10. Bland ML, **Jamieson CA**, Akana SF, Bornstein SR, Eisenhofer G, Dallman MF, Ingraham HA. Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response. Proc Nat Acad Sci. 97:14488-14493. PMID:11121051

11. Bland, M.L., **Jamieson, CA**, Akana, S., Dallman, M., and H. Ingraham. 2000. Gene dosage effects of steroidogenic factor 1 (SF1) in adrenal development and stress. Endocr Res. 26: 515-6.

12. Poon, M., Choi, S-H., **Jamieson, C.A.,** Geschwind, D. and K.C. Martin. 2006. Identification of Dendritically Localized mRNAs in Hippocampal Cultures. Journal of Neuroscience. 26(51):13390-9.

13. Zhou, H., Miki, R., Eeva, M., Yang, L., Seligson, D., Yoshimura, A., **Jamieson CA** and N. A. Cacalano. 2007. Aberrant regulation of SOCS1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 13(8): 2344-53.

14. Sitko J, Yeh B, Kim M, Zhou H, Takaesu G, Yoshimura A, McBride W, Jewett A, **Jamieson**, **C**, Cacalano NA. 2008. SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. *Cell Signal* 2008 Dec;20(12):2221-30. PMCID: PMC2676910

15. Peng L, Wu T-T, Tchieu JH, Feng J, Brown HJ, Li X, Qi J, Deng H, Vivanco I, Mellinghoff, IK, **Jamieson C**, Sun R. Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. *J. Gen. Virol.* 2010 Feb;91(Pt 2):463-469. PMID: 19864499.

16. Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, Topp K, Boso G, Jamieson CH, Cacalano NA, **Jamieson CA**. Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. *Neuromuscul Disord.* 2010 Feb;20(2):111-21. Epub 2010 Jan 18. PMID: 20080405

17. Anghel A, **Jamieson CA**, Ren X, Young J, Porche R, Ozigbo E, Ghods DE, Lee ML, Liu Y, Lutfy K, Friedman TC. Gene expression profiling following short-term and long-term morphine exposure in mice uncovers genes involved in food intake. *Neuroscience* 2010 May 5;167(2):554-66. Epub 2010 Feb 6. PMID: 20144693

18. Raheem, O., Kulidjian, A., Wu, C., Jeong, Y.B., Yamaguchi, T., Smith, K.M., Goff, D., Leu, H., Morris, S.H., Cacalano, N.A., Masuda, K., Jamieson, C.H.M., Kane, C.J., **Jamieson, CA**. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med. 2011 Oct 28;9:185-198 PMCID: PMC3269442

19. Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, **Jamieson CA**, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH. NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. PLoS One. 2012; 7(6):e39725. Epub 2012 Jun 29. PMID:22768113

20. Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, **Jamieson CA,** Morris SR, Messer K, Goldstein LS, Hudson TJ, Marra M, Frazer KA, Pellecchia M, Reed JC, Jamieson CH. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013 Mar 7;12(3):316-28. Epub 2013 Jan 17. PMID: 23333150

21. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, and **Jamieson CA**. Tumor Infiltrating B-cells are Increased in Prostate Cancer Tissue. J Transl Med. 2014 Jan 30;12:30. doi: 10.1186/1479-5876-12-30. PMID: 24475900.

22. Gobedu E, Muldong M, Strasner A, Wu C, Park SC, Woo JR, Ma W, Liss MA, Hirata T, Raheem O, Cacalano NA, Kulidjian AA, **Jamieson CAM**. PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer, is castrate-resistant in the bone niche. J Transl Med. 2014; 12:275 DOI: 10.1186/s12967-014-0275-1 PMCID: PMC4192441.

23. Ammirante M, Shalapour S, Kang Y, **Jamieson CAM,** Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci. U S A. 2014 Oct 14;111(41):14776-81. PMCID: PMC4205637

24. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, **Jamieson C,** Kane CJ, Klatte T, Birner, P., Kenner, L., Karin, M. TGFβ-induced immunosuppressive plasma cells are an impediment to successful T cell-dependent immunogenic chemotherapy. *Nature* 2015 May 7;521(7550):94-8. Epub 2015 Apr 29. PMID: 25924065

25. Hirata, T., Park, S.C., Muldong, M., Wu, C., Strasner, A., Cacalano, N.A., Yamaguchi, T., Kane, CJ, Kulidjian, A.A., Masuda, K., and **CAM Jamieson.** Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer. *Asian Journal of Urology, Special Edition, Guest Editor, LW Chung*. 2016 3: 229-239.

26. Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, **Jamieson C**, Kim WJ, Kim IY. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer. 2018 Jan 30. doi: 10.1038/bjc.2017.451. [Epub ahead of print]PMID:29381686

27. Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, **Jamieson C,** Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS. A Randomized, Double Blind, Phase II Trial of PSA-TRICOM (PROSTVAC®) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent

Progression on Active Surveillance Study (IPASS). Eur Urol Focus. 2018 Sep 6. pii: S2405-4569(18)30235-9. doi: 10.1016/j.euf.2018.08.016. [Epub ahead of print].

28. Grabowska M, Dong Y**, Jamieson CA**, Noon L, Dehm S, Gao A, Miranti C, Li X, Adam RM, Strand D, Cox MB. Precision Medicine in Urology: Molecular Mechanisms, Diagnostics and Therapeutic Targets - Report of the Society of Basic Urologic Research 2018 Annual Meeting. American journal of clinical and experimental urology. 2018 December; 6(Supplementary Issue 1):1-138.

29. Venkadakrishnan,VB, DePries, AD, Kumari, S, Senapati, D, Ben-Salem, S, Su, Y, Mudduluru, G, Hu, Q, Cortes, E, Pop,E, Mohler, JL, Azabdaftari, G, Attwood, K, **Jamieson CAM**, Dehm, SM, Magi-Galluzzi, C, Klein, E, Sharifi, N, Liu, S, and HV. Heemers**.** Protein Kinase N1 control of androgen-responsive Serum Response Factor action provides rationale for novel prostate cancer treatment strategy. Oncogene. 2019 Feb 11;. doi: 10.1038/s41388-019-0732-7. [Epub ahead of print] PubMed PMID: 30742064.

30. Lee, S, Burner, DN, Mendoza, TR, Muldong, MT, Arreola, C, Wu, CN, Cacalano, NA, Kulidjian, AA, Kane, CJ, **CAM Jamieson.** Three-Dimensional (3D) organoids from patient tumor specimens and patient-derived xenografts of bone metastatic prostate cancer and its applications. J Vis Exp. 2020 Feb 3;(156). doi: 10.3791/60367.

31. Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, **Jamieson C,** Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312. eCollection 2019. PMID: 31511835, PMCID: PMC6734039.

32. **Crumbaker M**, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, **Jamieson CAM**, Croucher PI, Hovens CM, Joshua AM, Hayes VM. The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis**.** Cancers (Basel). 2020 May 7;12(5):1178. doi: 10.3390/cancers12051178. PMID: 32392735 PMCID: PMC7280976 DOI: 10.3390/cancers12051178

33. Ryan, SR, Liss, M, Shabaik, A, Pittman, E, Muldong, M, Burner, DN, Zhang, J, Woo, JR, Shalapour, S, Karin, M, Messer, K, Howell, S, Kane, CJ and **CAM Jamieson**. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. *J Transl Med*. 2020 May 28;18(1):214. doi: 10.1186/s12967-020-02370-4.PMID: 32466781

https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/

Manuscripts in Peer Review (Research completed):

1. Lee, S, Mendoza, TR, Burner, DN, Muldong, MT, Wu, CN, Arreola, C, Zuniga, A, Miakicheva-Greenburg, O, Zhu, WY, Cacalano, NA, Jamieson, CHM, Christopher J. Kane, CJ, Kulidjian, AA, Gaasterland, T and **C.A.M. Jamieson.** Emergence of resistant basal-luminal cells and loss of SARS-CoV2 factors, ACE2 and TMPRSS2, in prostate cancer organoids under androgen deprivation therapy. (Submitted, **Cancer Cell**).

2. Ben-Salem, S, Venkadakrishnan, VB, MacDonald, JD, Bachour, S, Su, Y, DePriest, AD, Lee, S, Muldong, M, Kim, HT, Kumari, S, Valenzuela, MM, Hu, Q, Cortes, E, Dehm, SM, Zoubeidi, A, Wang, J, **Jamieson, CAM**, Nicolas, M, McKenney, J, Willard, B, Klein, EA, Magi-Galluzzi, C, Stauffer, SR, Liu, S and HV Heemers. Citron kinase drives prostate cancer progression and its inhibition overcomes treatment resistance. (Submitted, **Journal of Clinical Investigation**)

3. Ingmar Niels Bastian, Weihua Li, Laura Antonucci, Xi-he Zhao, Qui T Phung, Charles Robert Lichtenstern, Michelle Dow, Sourav Banerjee, Xue-Jia Lin, Hua Su, Jian Yu Huang, Brian Dang, Yixuan Zhou, Sylvia Choi, Andres Perkins, Shusil Pandit, **Christina Jamieson**, Kenneth Wong, Marcus Bosenberg, Zhang Cheng, Amanda Birmingham, Leila

Delamarre, Johannes Haybaeck, Lukas Kenner, Kathleen M. Fisch, Genevive Hernandez, Hannah Carter, Jennie R. Lill, Ira Mellman, Michael Karin, Shabnam Shalapour. Platinoid drugs augment immunotherapy via histone acetylation of MHCI machinery genes. (Submitted, **Nature Immunology**).

4. Jennifer S. Y. Ma, Sung Chang Lee, Min Soo Kim, Eric N. Hampton, Eduardo Laborda, Sei-Hyun Choi, Burzin Chavda, Michelle Muldong, Christina N. Wu, Wenxue Ma, Anna A. Kulidjian, Christopher J. Kane, **Christina A.M. Jamieson,** Ashley K. Woods, Sean Joseph, Timothy M. Wright, John Wisler, Peter G. Schultz, Chan Hyuk Kim, Travis S. Young . **Clinical development of bispecific PMSA-directed CD3 T-cell engager.** (Submitted, **Molecular Cancer Therapeutics).**

5. **Jamieson CA**, Petrigliano F, Belanto J, Virk M, Coppola G, Tchieu J, Fu E, Magyar C, Raheem O, Kazarian M, Morris SH, Cacalano NA, Geschwind DH, Jamieson CHM, Tetradis S, Lieberman JR. Genome-wide expression profiling of castration-resistant prostate cancer xenografts in the bone-niche revealed the upregulation of the anti-apoptosis gene, YWHAZ, a network module hub gene (In revision for re-submission).Here we show for the first time that prostate tumor growth in the bone microenvironment can by itself result in castrate-resistant prostate cancer and performed whole genome microarray gene expression profiling and identified gene networks associated with prostate cancer growth in the bone microenvironment.

Manuscripts in preparation:

1. **CAM Jamieson,** Kulidjian, A.A., Muldong, M, Wu, C., Lee, S., Mendoza, T., Burner, DN, Park, SC, Park, JS, Raheem, O., Woo, JR, Godebu, E., Strasner, A., Kane, CJ, Gaasterland, T. Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone. (Research completed, *Manuscript In Preparation,* **Target Journal:** *Science Translational Medicine*).
   "First-in-field" next generation genome sequencing and transcriptome analysis of a longitudinal series of surgical bone metastasis specimens from the same prostate cancer patient at different stages of disease progression and acquired resistance and his xenografts.

2. Muldong, MT, Lee, S, Wu, CN, Burner, DN, Mendoza, TR, Arreola, C, Zuniga, A, Murtadha, J, Cacalano, NA, Jamieson, CH, Kane, CJ, Kulidjian, AA., Gaasterland, T, and J**amieson, CAM,** Enzalutamide treatment of patient derived bone metastatic prostate cancer xenograft models implanted in the bone resulted in durable progression to castration resistant prostate cancer (CRPC). Target Journal: Cancer Cell.

3. Christina N. Wu[1,2], Michelle Muldong[1,3], Hyun Tae Kim[1,3,4], Sung Gu Kang[1,3,5], Sanghee Lee[1,3,6], Catriona H.M. Jamieson[1,2], Nicholas A. Cacalano[7], Christopher J. Kane[1,3], Anna A. Kulidjian[1,8], **Christina A.M Jamieson**[1,3,*] Use of Intra-femoral injection for patient-derived xenograft (PDX) model of bone metastatic prostate cancer (BMPC).

4. Michelle Muldong, **Christina Jamieson,** Yun Oliver Long, Ida Deichaite, Alan Lewis, David W. Anderson, Nicholas A. Cacalano. Novel epidermal growth factor receptor inhibitors cross the blood-brain barrier and inhibit the growth of EGFR+ brain metastatic non-small cell lung cancer. Target journal: Journal of Translation Medicine.

5. Lee, S., Burner, DN, Mendoza, TR, Muldong, MT, Kim, HT, Arreola, C, Wu, CN, McDermott, JJ, Narasimhan, RS, Murtadha, J, Kang, SK, Zuniga, A, Jamieson, CHM, Cacalano, NA, Kim, IY, Willert, K, Gaasterland, T, Kulidjian, AA, Mckay, RR, Kane, CJ, **Jamieson, CAM**. Targeting the WNT5A Receptor, ROR1, in Prostate Cancer**.** Target Journal: Cell Stem Cell.

6. Lee, S., Burner, DN, Mendoza, TR, Muldong, M., Arreola, C., Wu, CN, Strasner, A., Woo, J.R., Jamieson, CHM, Kulidjian, A.A., Kane, CJ and **CAM Jamieson**. Novel spontaneous advanced metastasis (SAM) model in 3D/organoid culture of a patient derived xenograft model for bone metastatic prostate cancer (Research completed, *Manuscript In Preparation, Target Journal: PLoSOne)*.

7. Muldong, M., Wu, C., Lee, S., Arreola, C., Burner, DN, Strasner, A., Woo, J.R., Liss, M., Yamaguchi, T., Jamieson, CHM, Kulidjian, A.A., Masuda, K., Kane CJ and **CAM Jamieson**. Characterization of new small cell bone metastatic prostate cancer patient-derived xenograft models from treatment-naive patients (Research completed, *Manuscript In Preparation, Target Journal:)*.

8. Burner, DN, Mendoza, TR, Muldong, M., Lee, S., Arreola, C., Wu, CN, Strasner, A., Woo, J.R., Jamieson, CHM, Kulidjian, A.A., Kane, CJ and **CAM Jamieson**. Anti-androgen response of new small cell patient-derived 3D/organoid models from bone metastatic prostate cancer specimens and matched xenografts (Research completed, *Manuscript In Preparation, Target Journal: Scientific Reports)*.

9. Lee, S., Burner, DN, Mendoza, TR, Muldong, M., Arreola, C., Wu, CN, Strasner, A., Woo, J.R., Jamieson, CHM, Kulidjian, A.A., Kane, CJ and **CAM Jamieson**. **Novel spontaneous advanced metastasis (SAM) model in 3D/organoid culture of a patient derived xenograft model for bone metastatic prostate cancer** (Research completed, *Manuscript In Preparation, Target Journal: PLoSOne)*.

10. Wu, C., Strasner, A., Muldong, M., Woo, J.R., Liss, M., Yamaguchi, T., Jamieson, CHM, Kulidjian, A.A., Masuda, K., and **CAM Jamieson**. Characterization of bone lesions in PCSD5 and PCSD13, new bone metastatic prostate cancer xenograft models derived from untreated patients (Research completed, *Manuscript In Preparation)*.

Published Abstracts

1. **Jamieson, C.,** McCaffrey, PG, Rao, A, Sen, R. The T cell antigen receptor mediates NF–κB induction. 1990. Cold Spring Harbor: RNA Tumor Viruses, P.46.1.

2. **Jamieson, C.A.M.,** Kristic, M., Yamamoto, KR. 1997. The Role of Phosphorylation in Glucocorticoid Receptor Function. Cold Spring Harbor: Tyrosine Phosphorylation and Cellular Signaling.

3. **Jamieson, CAM** and Yamamoto, KR. T cell antigen receptor rescue from glucocorticoid-induced apoptosis is mediated by the ERK MAP kinase pathway. 1999. Cold Spring Harbor Symposium: signaling and Gene Expression in the Immune System.

4. Miki, R., Nevarez, L. and **C. Jamieson.** Gene Regulatory Networks in Glucocorticoid-Induced T lymphocyte Apoptosis and Survival. 2003. Cold Spring Harbor Laboratory : Genome Informatics Meeting May 7-11, 2003.

5. Fu, E., Refela, J., Magyar, C., Miki, R., Tchieu, J., Petrigliano, F., Chao, L. Cho, P., Cacalano, N., Lieberman, J., Jasuja, R., Tetradis, S., and **C.A.M. Jamieson**, Keystone Symposium: Nuclear Receptors: Prostate cancer cells promote osteoblast differentiation in vitro which is modulated by androgen. Mar. 18- 23, 2006

6. Tchieu, JH, Miki, R, Mrejen, C, Nevarez, L, Kazarian, M, Refela, J, Fu, E, Paz, E, Cacalano, NA and **CAM Jamieson**, Keystone Symposium: Nuclear Receptors: Functional genomic analysis of dexamethasone-induced apoptosis in T lymphocyte cell lines. Mar. 18-23, 2006

7. Zhou H, Miki R, Eeva M, Fike FM, Seligson D, Yang L, Yoshimura A, Teitell MA, **Jamieson CAM**, Cacalano NA. Reciprocal regulation of SOCS1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. 53rd Annual Meeting of Radiation Research Society (RRS), Philadelphia, PA, November 5-8, 2006 (**Oral Presentation**).

8. **Jamieson, C.A.M.,** Belanto, J.J. , Magyar, C. E., Diaz-Perez, S. V., Mrejen, C. , Tchieu, J., Coppola, G., Miki, R., Kazarian, M. , Nevarez, L. , Topp, K. , Boso, G., Yilmaz, Y., Fu, E. , Maibaum, M. , Ahn, A.H. , Barczak, A. , Dye, C. , Lacy, E. ,

Timmerman, L. , Geschwind, D.H., Jamieson, C. H**.,** Cacalano, N. A., Apoptosis in dysferlin deficiency Jain Foundation 1st Annual Conference July 2007 (**Oral Presentation**).

9. Sitko, J, Zhou, H, Takaesu, G, Yoshimura, A, McBride, WH, Jewett, A, **Jamieson, CAM**, Cacalano, NA SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage Meeting of the American Association of Cancer Research (AACR) 2008: Abstract No. 5281.

10. J. Sitko , B . Yeh , M . Kim , H . Zhou , G . Takaesu , A . Yoshimura , W . McBride , A . Jewett, **C . Jamieson**, Cacalano, NA. SOCS3 Regulates p21 Expression and Cell Cycle Arrest in Response to Radiation-induced DNA Damage Proceedings of the American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting. 2008: Abstract No. 3165.

11. J. Sitko , B . Yeh , M . Kim , H . Zhou , G . Takaesu , A . Yoshimura , W . McBride , A . Jewett **C . Jamieson** , Cacalano, NA. SOCS3 Regulates p21 Expression and Cell Cycle Arrest in Response to DNA Damage . Cold Spring Harbor Meeting/Cell Cycle May 14-18, 2008.

12. **Jamieson, C.A.M.,** Belanto, J.J. , Magyar, C. E., Diaz-Perez, S. V., Mrejen, C. , Tchieu, J., Coppola, G., Miki, R., Kazarian, M. , Nevarez, L. , Topp, K. , Boso, G., Yilmaz, Y., Fu, E. , Maibaum, M. , Ahn, A.H. , Barczak, A. , Dye, C. , Lacy, E. , Timmerman, L. , Geschwind, D.H., Jamieson, C. H**.,** Cacalano, N. A., Dysferlin Regulation and Function in T-Cell Death and Survival. Jain Foundation 2nd Annual Conference June 2008 (**Oral Presentation**).

13. Anghel, A., **Jamieson, C.,** Justin Young, David E. Ghods, Kabirullah Lutfy, Yanjun Liu and Theodore C. Friedman **"**Gene expression profiling reveals short-term and long-term morphine exposure regulates genes involved in food uptake in mice" Accepted for presentation at The Endocrine Society's 90th Annual Meeting 2008 Abstract Number 852620.

14. Belanto, J., Diaz-Perez, S., Magyar, C., Yilmaz, Y., Topp, K., Cacalano, N.A., **C.A.M. Jamieson.** Glucocorticoid Treatment of Myoblasts Enhanced Myotube Formation via Dysferlin-dependent and Independent Pathways. Jain Foundation 3rd Annual Conference June 2009.

15. Zachary S. Zumsteg, Nicholas A. Cacalano, Joseph J. Belanto, Brian K. Yeh, Victoria Pham, **Christina A.M. Jamieson**, Keisuke Iwamoto, William H. McBride, Kwanghee Kim. Thiostrepton, a novel proteasome inhibitor, downregulates FoxM1 expression and is a radiosensitizing agent in glioblastoma multiforme. 2009 Radiation Research Society Annual Meeting.

16. Yeh, B, Belanto, J, Pham, V, Gobrial, M, Mishel, P, Jewett, A, **Jamieson, C**, Cacalano, N. SOCS4 and SOCS5 are potential radiation response modifiers in glioblastoma. American Society for Therapeutic Radiology and Oncology (ASTRO) Translational meeting, St. Louis, MO, September 11-12, 2009.

17. Daniel Jacob Goff, Annelie Abrahamsson-Schairer, Alice Shih, Jennifer M. Black, Ryan Chuang, Raymond J. Tesi, **Christina Jamieson**, and Catriona Jamieson The Broad Spectrum Bcl-2 Inhibitor Apogossypol Induces Apoptosis and Differentiation of Blast Crisis Chronic Myeloid Leukemia Stem Cells. **Blood (ASH Annual Meeting Abstracts), Nov 2009;** 114**: 3275.**

18. Yeh, B, Belanto, J, Pham, V, Gobrial, M, Mishel, P, Jewett, A, **Jamieson, C**, Cacalano, N. SOCS4 and SOCS5 are potential radiation response modifiers in glioblastoma. Radiological Society of North America (RSNA) 95th Scientific Assembly and Annual Meeting, Chicago, Ill. November 29-December 4, 2009 (**Oral Presentation**).

19. **Jamieson CA**, Petrigliano, F., Belanto, J.,Virk, M., Coppola, G., Tchieu, J., Fu, E., Magyar, C., Raheem, O., Kazarian, M., Morris, S. H., Cacalano, N.A., Geschwind, D.H., Jamieson, C.H.M., Tetradis, S., and Lieberman, J.R. 2011 Genome-wide expression profiling of castration resistant prostate cancer xenografts in the bone-niche revealed the upregulation of the anti-apoptosis gene, YWHAZ, a network module hub gene. J.Urology 2011 April;185, Issue 4, Supplement, Page e582.

20. **Jamieson CA**, Petrigliano, F., Belanto, J.,Virk, M., Coppola, G., Tchieu, J., Fu, E., Magyar, C., Raheem, O., Kazarian, M., Morris, S. H., Cacalano, N.A., Geschwind, D.H., Jamieson, C.H.M., Tetradis, S., and Lieberman, J.R. Genome-wide expression profiling of castration-resistant prostate cancer xenografts in the bone-niche revealed the upregulation of the anti-apoptosis gene, YWHAZ, a network module hub gene (**Abstract ID: 1106705** Moderated Poster Session at the 2011 Annual Meeting of the American Urological Association Education and Research Inc., Washington, DC, May 14-19, 2011).

21. Raheem, O., Kulidjian, A., Wu, C., Jeong, Y.B., Yamaguchi, T., Smith, K.M., Goff, D., Leu, H., Morris, S.H., Cacalano, N.A., Masuda, K., Jamieson, C.H.M., Kane, C.J., and **Jamieson, CAM.** A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J. Urology 2012 Supplement: Abstract:1206790 AUA 2012. (**Oral Presentation**).

22. **CAM Jamieson**, Muldong, M., Strasner, A., Wu, C., Park, S.C., Woo, J.R., Liss, MA, Raheem, O., Cacalano, NA, Kulidjian, A.A., and CJ Kane. Castrate-resistant growth in the bone niche of PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer. AACR The Translational Impact of Model Organisms in Cancer 11-5-2013 to 11-8-2013, San Diego, CA

23. **CAM Jamieson**, Muldong, M., Strasner, A., Wu, C., Park, S.C., Woo, J.R., Liss, MA, Raheem, O., Cacalano, NA, Kulidjian, A.A., and CJ Kane. Castrate-resistant growth in the bone niche of PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer.Annual PCF Scientific Retreat, scheduled for October 24-26, 2013 at the Gaylord National Hotel & Convention Center, National Harbor, MD.

24. **CAM Jamieson**, Muldong, M., Strasner, A., Wu, C., Park, S.C., Woo, J.R., Liss, MA, Raheem, O., Cacalano, NA, Kulidjian, A.A., and CJ Kane. New patient-derived xenograft models of bone metastatic prostate cancer. 2013 SBUR Fall Symposium, 11-21-2013 to 11-24-2013, Nashville TN

25. Woo JR*, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, and **Jamieson CA**. Tumor Infiltrating B-cells are Increased in Prostate Cancer Tissue. * presented by Jason R. Woo, 14th Annual Meeting of the Society of Urologic Oncology (SUO), Dec 4-6, 2013 Bethesda, MD.

26. Gobedu, E, Muldong, M., Strasner, A., Wu, C., Park, S.C., Woo, J.R., Liss, MA, Raheem, O., Cacalano, NA, Kulidjian, A.A., and **CAM Jamieson.** Castrate-resistant growth in the bone niche of PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer. AACR-PCF Conference on Advances on Prostate Cancer 2014 1/18/2014- 1/21/2014, San Diego, CA

27. Gobedu, E, Muldong, M., Strasner, A., Wu, C., Park, S.C., Woo, J.R., Liss, MA, Raheem, O., Cacalano, NA, Kulidjian, A.A., and **CAM Jamieson.** Castrate-resistant growth in the bone niche of PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer. Moores Cancer Center 10th Industry/Academia Translational Oncology Symposium, La Jolla, CA, Feb 20th, 2014.

28. Jiang S, Mose E, Coppola G, Lowy A, **Jamieson C**, *Cacalano NA. Suppressor of cytokine signaling (SOCS)-3 and the C-X-C chemokines CXCL1 and CXCL2 promote tumor aggressiveness and radiation resistance in pancreatic cancer. American Association for Cancer Research (AACR) Annual Meeting, April 5-9, 2014 San Diego, CA

29. **Jamieson CAM,** Wu C, Strasner A, Hirata T, Muldong M, Woo JR, Liss MA, Jeong YB, Yamaguchi T, Park SC, Leu HS, Morris SR, Cacalano NA, Masuda K, Jamieson CHM, Kulidjian, AA, Kane CJ. Castrate-resistant growth in the bone niche of PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer. AUA 2014 May 16-21, 2014 Orlando, FL.

30. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, and **Jamieson CA**. Tumor Infiltrating B-cells are Increased in Prostate Cancer Tissue. AUA 2014 May 16-21, 2014

Orlando, FL.

31. Godebu, E., Wu, CN, Strasner, A., Muldong, M., Woo, JR, Raheem, O., Karin, M., Jamieson, CHM, Anna Kulidjian, AA, Kane, CJ, **Jamieson CAM**: PCSD1, a novel xenograft model of bone metastatic prostate cancer derived from a patient treated with androgen deprivation therapy and radiation. San Diego, Ca, Presentation to be made by Dr. Godebu, Western Section WSAUA, Oct 26-30, 2014, Grand Wailea, Maui, HI.

32. Hirata, T, Park, SC, Muldong, M, Strasner, A, Kumon, H, Kulidjian, AA, Kane, CJ, Masuda, K, **CAM Jamieson** Micro CT analysis for novel xenograft model of bone metastatic prostate cancer. The 52nd Annual Meeting of Japan Society of Clinical Oncology, Aug/28-30/2014 in Yokohama, Japan

33. Hirata, T, Park, SC, Muldong, M, Strasner, A, Kumon, H, Kulidjian, AA, Kane, CJ, Masuda, K, **CAM Jamieson** Microstructural analysis for novel xenograft model of bone metastatic prostate cancer. Society of International Urology (SIU), October 12-15, 2014 in Glasgow, UK

34. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. Prostate Cancer Foundation (PCF) 21st Annual Scientific Retreat, October 23-25, 2014, in Carlsbad, CA.

35. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. Society for Basic Urologic Research (SBUR), Dallas, TX Nov 13-16, 2014.

36. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. Moores Cancer Center 11th Industry/Academia Translational Oncology Symposium, La Jolla, CA, Feb 19th, 2015.

37. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. American Urologic Association (AUA) Annual Conference, New Orleans, LA, May 14th-19th, 2015

38. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. 4th Annual Dept of Surgery Research Conference, UCSD, La Jolla CA , June 9th - 10th 2015

39. Jason R. Woo, Michael A. Liss, Michelle T. Muldong, Kerrin Palazzi, Amy Strasner, Massimo Ammirante, Nissi Varki, Ahmed Shabaik, Stephen Howell, Christopher J Kane, Michael Karin, and **Christina A.M. Jamieson***. **Tumor Infiltrating B-cells are Increased in Prostate Cancer Tissue"** Digital Pathology Congress USA, June 22-23, 2015, San Diego, USA

40. **Jamieson CAM**. Godebu, E, Muldong, M., Strasner, A., Wu, CN, Park, SC, Woo, JR, Ma, W., Liss, MA, Hirata, T., Raheem, O., Cacalano, NA, Kane, CJ, Kulidjian, AA, PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. The Prostate Cancer Foundation's 22nd Annual Scientific Retreat, Washington DC, Oct 7th-10th, 2015.

41. Hirata, T, Park, SC, Muldong, M, Strasner, A, Kumon, H, Jamieson, CHM, Kulidjian, AA, Kane, CJ, Masuda, K, **CAM Jamieson** Bone Microenvironment Region-Specific Localization of Lesion Morphology Patterns in PCSD1, a Patient-

Derived Xenograft Model of Bone Metastatic Prostate Cancer. Society for Basic Urologic Research (SBUR) Annual Fall Conference, Fort Lauderdale, FL, Nov 12th-15th, 2015.

42. **CAM Jamieson**, Muldong, M, Long, Y.O., Deichaite, I., Lewis, A., Anderson, D.W., Cacalano, N.A*. Novel epidermal growth factor receptor inhibitor accumulates in the brain and inhibits the growth of brain metastatic non-small cell lung cancer. Fourth AACR-IASLC Joint International Conference on Lung Cancer Translational Science from the Bench to the Clinic from January 4-7, 2016 in San Diego, CA. Plenary Session 6: **Proffered Talks from Highly Rated Abstracts on Thursday, January 7, 2016.**

43. **C.A.M. Jamieson,** Muldong, M, Liss, MA, Park, SC, Mendoza, T, Gallegos, A., Edsall, LE, Nseyo, U, Miakicheva, O, Burton, B, Burner, D, Strasner, A, Kane, CJ, Kulidjian, AA, T Gaasterland. Full exome sequencing, copy number variation and transcriptome analyses reveals diversity and mutational evolution in a longitudinal series of surgical prostate cancer bone metastases from a patient with progressively therapy-resistant cancer. American Urologic Association (AUA) Annual Conference, 2016 May 6-10, 2016 San Diego, CA

44. **C.A.M. Jamieson,** Muldong, M, Liss, MA, Park, SC, Mendoza, T, Gallegos, A., Edsall, LE, Nseyo, U, Miakicheva, O, Burton, B, Burner, D, Strasner, A, Kane, CJ, Kulidjian, AA, T Gaasterland. Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone. 5th Annual Dept of Surgery Research Symposium Oral presentation. June 14th, 2016, San Diego CA

45. **C.A.M. Jamieson,** Muldong, M, Liss, MA, Park, SC, Mendoza, T, Gallegos, A., Edsall, LE, Nseyo, U, Miakicheva, O, Burton, B, Burner, D, Strasner, A, Kane, CJ, Kulidjian, AA, T Gaasterland. Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone. Association of Molecular Pathology (AMP) Annual Conference, Nov. 8-10, 2016, Charlotte, NC

46. **C.A.M. Jamieson,** Muldong, M, Liss, MA, Park, SC, Mendoza, T, Gallegos, A., Edsall, LE, Nseyo, U, Miakicheva, O, Burton, B, Burner, D, Strasner, A, Kane, CJ, Kulidjian, AA, T Gaasterland. Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone. Society of Basic Urologic Research (SBUR) Annual Fall Symposium Nov 10-13, 2016, Scottsdale AZ

47. **C.A.M. Jamieson**, Muldong, MT, Gallegos, A, Wu, CN, Mendoza, T, Park, JS, Zhu, W, Raheem, O, Park, SC, Liss, MA, Burner, D, Edsall, LE, Miakicheva, O, Cacalano, NA, Jamieson, CHM, Kane, CJ, Kulidjian, AA, Gaasterland, T. Genomic Analysis of a Longitudinal Series of Surgical Prostate Cancer Bone Metastases and Xenografts from the Same Patient Revealed Selection of a Progressively Therapy Resistant Metastatic Clone. American Urologic Association (AUA) 2017 Annual Conference, May 12-16, 2017 Boston MA (Accepted).

48. Mendoza, TR, Muldong, MT, Burner, D Gallegos, A, Wu, CN, Edsall, LE, Park, JS, Liss, MA, Raheem, O, Park, SC, Zhu, W, Godebu, E, Woo, JR, Strasner, A, Miakicheva, O, Cacalano, NA, Jamieson, CHM, Kane, CJ, Kulidjian, AA, Gaasterland, T and **C.A.M. Jamieson.** Heterogeneity and Drug Resistance in 3D Cultures of Patient Prostate Cancer Bone Metastases and Primagrafts. 24th Annual Prostate Cancer Foundation Scientific Retreat 2017, Oct 4-7, 2017, Washington DC.

49. Mendoza, TR, Muldong, MT, Burner, D Gallegos, A, Wu, CN, Edsall, LE, Park, JS, Liss, MA, Raheem, O, Park, SC, Zhu, W, Godebu, E, Woo, JR, Strasner, A, Miakicheva, O, Cacalano, NA, Jamieson, CHM, Kane, CJ, Kulidjian, AA, Gaasterland, T and **C.A.M. Jamieson.** Heterogeneity and Drug Resistance in 3D Cultures of Patient Prostate Cancer Bone Metastases and Primagrafts. Society for Basic Urologic Research (SBUR) Annual Fall Symposium, Joint Meeting with ESUR, Nov 9-12, 2017, Tampa, FL. Am J Clin Exp Urol 2017; 5 (Suppl 1): 1-92
www.ajceu.us / ISSN:2330-1910/2017 SBUR Annual Meeting.

50. Ryan, S., **Jamieson, CAM**, Shabaik, A, Pittman, E., Zhang, J., Muldong, M., Shalapour, S., Karin, M., Messer, K., Howell, S. and C.J. Kane MP70-20 B CELL CONCENTRATION IN HIGH RISK PROSTATE CANCER SPECIMENS AFTER NEOADJUVANT RITUXIMAB The Journal of Urology, Vol. 199, Issue 4, e942 Published in issue: April 2018

51. Ryan, ST, Liss, M, Shabaik, A, Pittman, E, Muldong, M, Burner, DN, Zhang, J, Woo, JR, Shalapour, S, Karin, M, Messer, K, Howell, S, Kane, CJ and **Jamieson, CAM**. **PROTUX Clinical trial: An open label, single institution, pilot study of rituximab neoadjuvant therapy in patients with high risk prostate cancer scheduled to undergo radical prostatectomy.** Society for Basic Urologic Research (SBUR) Annual Fall Symposium, Nov 8-11, 2018, Palm Springs, CA. AJCEU 2018.

52. Muldong, M., Burner, D., Wu, CN, Mendoza, T., Arreola, C., Lee, S., Jamieson, CHM, Cacalano, NA, Kulidjian, AA, Kane, CJ, **Jamieson, CAM**. **Enzalutamide Treatment Results in Anti-Androgen Resistance in Patient Derived Bone Metastatic Prostate Cancer Models.** Society for Basic Urologic Research (SBUR) Annual Fall Symposium, Nov 8-11, 2018, Palm Springs, CA. AJCEU 2018.

53. Burner, DN, Mendoza, TR, Muldong, MT, Lee, S., Arreola, C., Miakicheva-Greenburg, O, Zhu, W, Wu, CN, Jamieson, CHM, Cacalano, NA, Kulidjian, AA, Kane, CJ, **Jamieson, CAM**. **Mechanisms of anti-androgen resistance in a 3D patient-derived organoid (PDO) model of bone metastatic prostate cancer.** Society for Basic Urologic Research (SBUR) Annual Fall Symposium, Nov 8-11, 2018, Palm Springs, CA. AJCEU 2018.

54. **Lee, S.*,** Arreola, C., Burner, D., Muldong, M., Mendoza, T., Wu, CN, Jamieson, CHM, Cacalano, NA, Kulidjian, AA, Kane, CJ, **Jamieson, CAM**. **Prostate cancer bone metastasis patient-derived three-dimensional organoids undergo a budding-like cell extrusion process to form cyst/gland-like structures: an in vitro model of metastatic tumor formation.** Society for Basic Urologic Research (SBUR) Annual Fall Symposium, Nov 8-11, 2018, Palm Springs, CA. AJCEU 2018. ***Winner of Travel Award SBUR 2918 Fall Symposium**

55. **Burner, DN,** Mendoza, TR, Muldong, MT, Lee, S., Arreola, C., Miakicheva-Greenburg, O, Zhu, W, Wu, CN, Jamieson, CHM, Cacalano, NA, Kulidjian, AA, Kane, CJ, Jamieson, CAM. **Mechanisms of anti-androgen resistance in a 3D patient-derived organoid (PDO) model of bone metastatic prostate cancer. Moderated Poster MP81, American Urologic Association (AUA) Annual Conference 2019, May 3-6, 2-19, Chicago, IL**

56. Muldong, M., Burner, D., Wu, CN, Mendoza, T., Arreola, C., Lee, S., Jamieson, CHM, Cacalano, NA, Kulidjian, AA, Kane, CJ, **Jamieson, CAM.** Enzalutamide Treatment Results in Anti-Androgen Resistance in Patient Derived Bone Metastatic Prostate Cancer Models, Moderated Poster MP68, American Urologic Association (AUA) Annual Conference 2019, May 3-6, 2-19, Chicago, IL

57. **Jamieson, CAM,** Lee, S., Burner, DN, Mendoza, TR, Muldong, MT, Zuniga, A, Arreola, C, Wu, CN, McDermott, JJ, Narasimhan, RS, Kang, SK, Jamieson, CHM, Cacalano, NA, Kim, IY, Willert, K, Gaasterland, T, Kulidjian, AA, Mckay, RR, Kane, CJ, Targeting the WNT5A Receptor, ROR1, in Prostate Cancer. "," Speaker and Poster, Prostate Cancer Foundation (PCF) 26th Annual Scientific Retreat, October 24-27th, 2019, Carlsbad, CA.

58. Lee, S., Burner, DN, Mendoza, TR, Muldong, MT, Zuniga, A, Arreola, C, Wu, CN, McDermott, JJ, Narasimhan, RS, Kang, SK, Jamieson, CHM, Cacalano, NA, Kim, IY, Willert, K, Gaasterland, T, Kulidjian, AA, Mckay, RR, Kane, CJ, **Jamieson, CAM**. Targeting the WNT5A Receptor, ROR1, in Prostate Cancer**.** "*Novel Discoveries in Urology: Big Data to Microbiome*," November 7 -10, 2019, Society for Basic Urologic Research (SBUR) Nov 2019, New Orleans, LA.

59. **Jamieson, CAM,** Muldong, MT, Lee, S, Wu, CN, Burner, DN, Mendoza, TR, Arreola,C, Zuniga, A, Cacalano, NA, Jamieson, CH, Kane, CJ, Kulidjian, AA. Enzalutamide treatment of patient derived bone metastatic prostate cancer xenograft models implanted in the bone resulted in durable progression to castration resistant prostate cancer (CRPC). American Association for Cancer Research (AACR) Annual Conference 5/27/20-5/29/20: Virtual Poster #6109 presentation, May 28th, 2020.

60. Pham, H, Sadler, GR, France Nguyen-Grozavu, F. and **Jamieson CAM**, Promising Strategies to improve Prostate Cancer death rate among Native Americans and Alaska Natives Oct, 2020 International Cancer Education Conference

61. Corral Pineda, N, Sadler, GR, France Nguyen-Grozavu, F. and **Jamieson CAM** Hispanic Acculturation May Put Them at a Higher Risk of Having Liver Cancer Oct, 2020 International Cancer Education Conference

62. Gaasterland, T, Lee, S, Mendoza, T, Burner, D, Muldong, MT, **CAM Jamieson**, Intersecting bone metastasis organoid transcriptomes to identify therapy response and resistance signals. American Society of Human Genetics 2020 Virtual Conference, Oct 27-30, 2020.

63. Lee, S., Muldong, MT, Kang, SK, Kane, CJ, Hsu, J, Salamsi, **Jamieson, CAM**. Three-dimensional (3D) co-culture system for organoids plus tissue infiltrating lymphocytes (TILs) derived from patient benign normal and hyperplastic proliferative ureter specimens. Society for Urological Research (SBUR) Annual Meeting, Nov11-14, 2020 Virtual.

64. **Jamieson, CAM**, Lee, S, Mendoza, TR, Burner, DN, Muldong, MT, Wu, CN, Arreola, C, Zuniga, A, Miakicheva-Greenburg, O, Zhu, W, Cacalano, NA, Jamieson, CH, Kane, CJ, Kulidjian, AA, Gaasterland, T. Emergence of novel basal-luminal hybrid cells and loss of SARS-CoV-2 factors, TMPRSS2 and ACE2, in prostate cancer organoids under androgen deprivation treatment. Society for Urological Research (SBUR) Annual Meeting, Nov11-14, 2020 Virtual.

65. Muldong, M, Oh, C, Velez Luhan, J, Wu, C, Lee, S, Prussak, CP, **CAM Jamieson**. Advancing anti-ROR1 CAR-T cells employing a cirmtuzumab based T-cell CAR to eradicate lethal castration resistant ROR1^{pos} prostate cancer. Society for Urological Research (SBUR) Annual Meeting, Nov11-14, 2020 Virtual.

Doctoral Thesis

Jamieson, CAM. Ph.D. Thesis, Advisor: Ranjan Sen, Ph.D "The Transcription Factor, NF–κB: Physiologic Activation, Function and Associating Proteins.", Dept. of Biology, Brandeis University, Waltham, MA, 1993.

Media

1. **Science,** June 3, 2020 News: Why coronavirus hits men harder: sex hormones offer clues By Meredith Wadman Jun. 3, 2020 https://www.sciencemag.org/news/2020/06/why-coronavirus-hits-men-harder-sex-hormones-offer-clues

2. **Press release link http://www.marketwired.com/press-release/-1941697.htm** for Targazyme, Inc. latest press release on the SBIR award from the National Institute of Dental and Craniofacial

3. ScienceToday Radio Program # 650: Researchers Uncover a Chemical Pattern Linked to Immune Cell Survival. **http://www.ucop.edu/sciencetoday/ramfiles/650c.ram** (for transcript and audio) Oct. 9, 2000

4. **Press Release**: UCSF Researchers Decipher Chemical "Crosstalk" That Determines Survival of Immune Cells. http://www.ucsf.edu/daybreak/2000/06/20_deciphering.html June 19, 2000

EDITORIAL AND REVIEW ACTIVITIES

Peer Reviewer

Journals

Molecular and Cellular Biology, Reviewer, 2006- present

NeuroReports, American Journal of Pathology, Reviewer, 2008- present

American Journal of Pathology, Reviewer, 2009- present

Nature Biotechnology, Reviewer, 2009- present

Prostate Cancer and Prostatic Diseases, Reviewer, 2010-present

iConcept, Reviewer, 2012- present

Cancer Research, Reviewer, 2017-present

Oncogene, 2018, 2019

The Prostate, 2019

Grant Review Panels:

UCSF AIDS Clinical Research Center, Reviewer, 1993-2000

Human Gene Medicine Program, Jonsson Comprehensive Cancer Center UCLA, Reviewer, 2003 - 2010

Prostate Cancer Foundation (PCF) Programmatic Review Panel, 2014

Department of Defense CDMRP Prostate Cancer Research Program Review Panel, FY2012, FY2013, FY2015, FY2016, FY2017, FY2018, FY2019

American Cancer Society, UC San Diego Moores Cancer Center, 2012- present

UCSD CTRI Pilot Project Applications, 2016-present

Editorial Boards

9/2014 - Present Scientific Reports (Nature Publishing Group)

PRESENTATIONS

Selected Invited Lectures, Academic (2005-present):

NICHD Directors Meeting, Bethesda MD Androgen receptor (AR) in bone metastasis *May18th, 2005*

Molecular Medicine, Charles R. Drew University, Torrance, CA. *April 3, 2006*
Model systems for prostate cancer-induced bone metastasis

NIH-NIAID, UCLA Center for Biological Radioprotectors (CBRP) *May 5, 2006*
External Advisory Committee Meeting:Small molecule screen for novel activators of radioprotection via STAT3

Dept. of Urology, UCLA Annual Research Conference: *Jan 2007*
Role of the androgen receptor (AR) in prostate cancer induced bone metastasis.

Cedars-Sinai Medical Center, Medical Genetics Institute Seminar Series *Jan., 2007*
Model systems for understanding steroid hormone receptors in cancer:
A functional genomics approach

Jain Foundation First Annual Dysferlin Conference, Hamilton, Bermuda *July, 2007*
Apoptosis in Dysferlin deficiency

NIH-NIAID,UCLA Center for Biological Radioprotectors (CBRP) Seminar Series *July, 2007*
Small molecule screen for novel activators of radioprotection via STAT3

MOLAR, Meeting of Los Angeles Area Receptor groups,
Beckman Center, City of Hope, Duarte, CA
Functional genomics of glucocorticoid-induced apoptosis in T cells *Oct,2007*
revealed novel role of membrane modulators

Dept. of Biology, California State University, Fullerton (CSUF) *Nov, 2008*
Glucocorticoids, T cell apoptosis and muscular dystrophy: the Dysferlin connection

Jain Foundation Second Annual Dysferlin Conference, San Juan, Puerto Rico *June, 2008*
Dysferlin Induction in Apoptosis and muscle

Endocrinology Division, Charles R. Drew University, Torrance CA *Dec, 2008*
Functional genomics of T cell apoptosis and muscular dystrophy:
the Dysferlin connection

Dept. of Neurology Grand Rounds
UCLA, Los Angeles, CA *Feb. 3, 2010*
The immune system and muscular dystrophy: the dysferlin connection

Div. of Urologic Oncology, UCSD Moores Cancer Center
UC San Diego, La Jolla, CA *Mar 31, 2010*
Model systems for prostate cancer-induced bone metastasis. Host: Dr. C. Kane.

MOLAR, Meeting of Los Angeles Area Receptor groups,
Beckman Center, City of Hope, Duarte, CA
Bone niche, networks and castration resistant prostate cancer *Dec 8,2010*

Annual Conference of the America Urological Association *May 17, 2011*
Washington, DC
Genome-wide expression profiling of castration resistant prostate cancer xenografts
in the bone-niche revealed the upregulation of the anti-apoptosis gene, YWHAZ,
a network module hub gene.

Annual Conference of the America Urological Association *May, 2012*
Atlanta, GA
Novel patient-derived model of bone metastatic prostate cancer.

American Association for Cancer Research Annual Conference 2013, xCELLigence
User Symposium Washington, DC *April 6, 2013*
Use of xCELLigence in Prostate Cancer Research

San Diego State University, Dept of Biology,
San Diego, CA *Oct. 10, 2013*
Castrate-resistant growth in the bone-niche of novel patient-derived
xenograft models of bone metastatic prostate cancer.

Garvan Institute of Medical Research, The Kinghorn Cancer Center, Sydney, Australia *Dec.11, 2013*
Castrate-resistant growth in the bone-niche of novel patient-derived xenograft models of bone metastatic prostate cancer.

American Association for Cancer Research Annual Conference 2013, xCELLigence User Satellite Symposium, San Diego, CA *April 4-5, 2014*
Use of xCELLigence in Bone Metastatic Prostate Cancer Research

Huzhou City, Zheijiang Province, China *June 27-29, 2014*
Plenary Speaker: Castrate-resistant growth in the bone-niche of novel patient-derived xenograft models of bone metastatic prostate cancer.
2014 South Lake Taihu International Conference on Cancer Therapy and Nursing Sciences

The Inaugural Leo and Anne Albert Charitable Trust Workshop *Feb 27th, 2015*
Reducing the Burden of Bone Metastatic Prostate Cancer
New patient-derived xenograft models for bone metastatic prostate cancer
Hyatt Regency La Jolla at Aventine, La Jolla, CA

UCSD Medical Center, Anesthesia Research Lab, *April 9th , 2015*
New patient-derived xenograft models for bone metastatic prostate cancer
Host. Dr. Tony Yaksh
Hillcrest, San Diego, CA

UCSD Moores Cancer Center, Cancer Biology and Signaling Program Retreat *May 2nd, 2015*
New patient-derived xenograft models for bone metastatic prostate cancer
UCSD Moores Cancer Center, La Jolla, CA

American Urological Association (AUA) 2015 Annual Conference oral presentation *May 18th, 2015*
MicroCT analysis revealed bone region-specific localization of osteolytic versus osteoblastic lesions in PCSD1, a new patient-derived xenograft model of bone metastatic prostate cancer.
Winner Best Moderated Poster and Oral Presentation
New Orleans, LA

Cedars-Sinai Medical Center Uro-Oncology Research Program *June 15th, 2015*
New patient-derived xenograft models for bone metastatic prostate cancer
Host: Dr. Leland W. Chung, Board of Governors Chair in Cancer Research
Director, Uro-Oncology Research Program in the Samuel Oschin Comprehensive Cancer Institute, Professor, Medicine
Beverly Hills, Los Angeles, CA

Digital Pathology Congress USA, *June 22-23, 2015*
Tumor Infiltrating B-cells are Increased in Prostate Cancer Tissue
San Diego, USA

UCSD Dept of Orthopedic Surgery Grand Rounds *Nov 4th, 2015*
Metastatic Prostate Cancer to Bone - From Bench to Bedside
UCSD Medical Center, Hillcrest, San Diego, CA

Society for Basic Urologic Research (SBUR) Fall 2015 Symposium – Fort Lauderdale, FL *Nov 14th , 2015*
November 12-15, 2015 Emerging Model Systems for Research
Fort Lauderdale, FL

Cellular and Molecular Immunology in Health and Disease *Jan 30th, 2016*
In honor of Dr. Ranjan Sen 60th Birthday Symposium
Brandeis University, Waltham MA

UCSD Moores Cancer Center Industry/Academia Translational Science Symposium *Feb 25, 2016*
The Bone Niche and Therapy Resistance in Bone Metastatic Prostate Cancer
La Jolla CA

Pacific Southwestern Regional Genetics Symposium *April 2, 2016*
Genoptix Medical Laboratory, Carlsbad, CA
The Bone Niche and Therapy Resistance in Bone Metastatic Prostate Cancer

American Urological Association (AUA) 2016 Annual Conference oral presentation *May 10, 2016*
Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone.

UCSD Pathology Research Lecture Series *May 23rd, 2016*
Leichtag Biomedical Research Bldg, UCSD, La Jolla CA
The Bone Niche and Therapy Resistance in Bone Metastatic Prostate Cancer

Exploring the Tumor Microenvironment: Affymetrix Lunch and Learn Symposium *June 07, 2016*
The Bone Niche and Therapy Resistance in Bone Metastatic Prostate Cancer
The Farmer and the Seahorse, La Jolla CA

5th Annual Dept of Surgery Research Symposium, UCSD, *June 14, 2016*
Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone.
UCSD Faculty Club La Jolla, CA

Association of Molecular Pathology (AMP) 2016 Annual Conference, Genomic analysis of *Nov. 9, 2016*
a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone.
Charlotte Convention Center, Charlotte, NC.

Laboratory of Molecular Biology and Immunology, The Bone Niche and Therapy Resistance *Jan 21, 2017*
in Bone Metastatic Prostate Cancer Biomedical Research Center, National Institutes of Health, National Institute of Aging, Baltimore, MD

Oral Presentation, Prostate Cancer: Basic Research, AUA 2017 Annual Meeting, Boston MA *May 15th, 2017*
Winner Best Moderated Poster and Oral Presentation,
Genomic analysis of a longitudinal series of surgical prostate cancer bone metastases and xenografts from the same patient with progressively therapy-resistant cancer revealed selection of metastatic clone.

University of Arizona Cancer Center, Tucson, AZ, Cancer Center Seminar Series. *Oct. 16th, 2017*
Developing and translating therapies for bone metastatic prostate cancer using new preclinical models.

4th Annual UC San Diego Division of Regenerative Medicine Symposium *March 9th, 2018*
Developing & Translating Therapies for Bone Metastatic Prostate Cancer
using new patient derived xenograft models. La Jolla, CA

American Urological Association (AUA) Annual Conference 2018 San Francisco, CA *May 19th, 2018*
Society for Basic Urologic Research (SBUR) Symposium: Novel Models And Emerging Therapies
Moderator and Presenter: Developing & Translating Therapies for Bone Metastatic prostate
cancer using new preclinical models.

UCSD Urology Research Symposium, UCSD Moores Cancer Center, La Jolla Ca *Sept.22, 2018*
Developing and Translating Novel Cancer Immunotherapies Sept 21-22, 2018

American Urologic Association (AUA) Annual Conference 2019, *May 3-6, 2019*
Enzalutamide Treatment Results in Anti-Androgen Resistance in Patient Derived Bone
Metastatic Prostate Cancer Models, Chicago, IL

Prostate Cancer Foundation (PCF) Sept 2019 WNT Journal Club 9-19-*2019*

UCSD Urology Research Symposium, UCSD Moores Cancer Center, La Jolla Ca 10-4-*2019*
Developing and Translating Novel Cancer Immunotherapies for Prostate Cancer

Prostate Cancer Foundation (PCF) 2019 Annual Retreat Speaker 10-26-2019
Targeting the WNT5A receptor, ROR1, in prostate cancer

UCSD GU Translational Research Monthly Meeting
Therapeutic targeting of prostate cancer stem cells using Cirmtuzumab. 11/2019

Prostate Cancer Foundation (PCF) Global Exchange Network Virtual Symposium 5-13-2020
"TMPRSS2 biology, pathobiology and epidemiology" Speaker

Society of Urologic Oncology (SUO)/ Society for Basic Urologic Research (SBUR) Joint 5-16-2020
Virtual Symposium, Annual Conference of the American Urological Association (AUA)
Developing and Translating Novel Cancer Immunotherapies for Prostate Cancer

Moores Cancer Center Solid Tumor Therapy (STT) Annual Retreat Virtual Conference, 9-18-2020
Patient-derived models for bone metastatic prostate cancer

La Jolla Immuno-oncology Interest Group (**iOiG**), Monthly Seminar Series 10-4-2020
Developing and Translating Novel Cancer Immunotherapies for Prostate Cancer

University of Tennessee Health Science Center, Cancer Research Grand Rounds 10-27-2020
Developing and Translating Novel Therapies Using Patient-Derived Models for Prostate Cancer

PROFESSIONAL MEMBERSHIPS / ACTIVITIES

American Association for the Advancement of Science, Member, 1993- present

Postdoctoral Scholar Association, UCSF, Member, 1995-2000

Juvenile Diabetes Foundation, Member, 1995-present

Arthritis Foundation, Member, 1997- present

Society for Basic Urologic Research (SBUR), Member, 2003- present

Muscular Dystrophy Association (MDA), Member, 2009-2018

Radiation Research Society (RRS), Member, 2007- present

American Urological Association (AUA), Member, 2010- present

Organization of National or International Conferences/Symposia (include chairing session)

Organizer, Session Chair and Speaker, The Second Urology Research Symposium, Oct 4th, 2019, UCSD Moores Cancer Center, La Jolla CA

Organizer and Chair, The First Leo and Anne Albert Symposium on Current Therapy and Future Directions in Bone Metastatic Prostate Cancer: from Palliation to Cure. Feb 27-28, 2015, Hyatt Regency, La Jolla at Aventince, La Jolla, CA.

Organizer and Chair, The Leo and Anne Albert Symposium Second Workshop on Bone Metastatic Prostate Cancer. Mar. 9th-11th, 2017, The Lodge at Torrey Pines, La Jolla, CA.

Chair, Morning Session Society of Urologic Oncology (SUO)/ Society for Basic Urologic Research (SBUR) Joint 5-16-2020 Virtual Symposium, Annual Conference of the American Urological Association (AUA) Developing and Translating Novel Cancer Immunotherapies for Prostate Cancer

Organizer, Session Chair and Speaker, Inaugural Urology Research Symposium, Sept 21-22, 2018, UCSD Moores Cancer Center, La Jolla CA

TEACHING:

Institutional Courses

Course Leader and Instructor, HG282, Fall, Winter, Spring 2004-2010, Dept. of Human Genetics, UCLA Created and taught core curriculum Human Genetics graduate program seminar class and Journal Club;. http://www.genetics.ucla.edu/courses/hg282/, Jan.2004- June 2010

Guest lecturer: Scripps Institute of Oceanography: SIO190 "*Advanced Tools and Data Challenges for Bioinformatics*" May 1st, 2018 Class Director: Terry Gaasterland.

Guest lecturer: Scripps Institute of Oceanography: SIO190 "*Advanced Tools and Data Challenges for Bioinformatics*" April 29th, 2019 Class Director: Terry Gaasterland.

Guest lecturer: Scripps Institute of Oceanography: SIO190 "*Advanced Tools and Data Challenges for Bioinformatics*" May 29th , 2020 Class Director: Terry Gaasterland.

Supervisory Committee/Mentor

Doctoral Thesis Committee Membership

Thesis Advisory Committee, Kim Le, Dept. of Biological Chemistry, Mentor: Dr. Michael Carey, 2004-2005
Thesis Advisory Committee, Mark Chin, Dept. of Molecular and Medical Pharmacology, Mentor: Dr. Desmond Smith, 2004-2007
Thesis Advisory Committee, Ali Kuraishy, MIMG, Mentor: Dr. Michael Teitell, 2004-2007
Thesis Advisory Committee, Yin Shen, Dept. of Human Genetics, Mentor: Dr. Guoping Fan, 2005-2009

Direct Supervision

Undergraduate Students

UCLA Undergraduate student research program (SRP):

- Meleeneh Kazarian, 2004
- Jane Refela, 2004-2005
- Emily Fu, 2005-2007
- Lisa Chao, 2006-2007
- Peter Cho, 2005-2006
- Joseph Belanto,
- Cynthia Chen,
- Kasey Topp,
- Guney Boso,
- Aditi Shrivastava,
- Sandeep Walia,
- Claire deCreszenzo

UCSD Undergraduate Students:

- Evodie Koutouan, Senior, Biology Program, UCSD August 2020 -present
- Naomi Corral, Junior, Biology Program, UCSD June 2019- present
- Hao Pham, Junior, Biology Program, UCSD June 2019- present
- Zoe Flores, Freshman, Biology Program, UCSD June 2018- Sept. 2018
- Jamillah Murtadha, Senior, Biology Program, UCSD June 2018- Aug 2020
- Abril Zuniga, Junior, Biology Program, UCSD June 2017- Aug 2019
- Duy Tong, Junior, Biology Program, UCSD June 2017- June 2018
- Catalina Arreola, Junior, Biology Program, UCSD June 2016- Aug 2019
- Theresa Mendoza, Junior, Biology Program, UCSD June 2014-Aug 2016
- Danielle Burner, Senior, Bioengineering, UCSD, June 2014-2018
- Brenda Delgado, Senior BISP and Qualifying year, Jan 2016-June 2017

UCSD Medical Students

- Deborah Marshall, 3rd year medical student, UCSD, July 2012-2013.
- Olga Miakicheva, June, 2015 – present Summer Research Internship, Albert Foundation, Mentor, Independent Study Program (ISP)
- Brittany Burton, June 2015-Sept 2015 Summer Research Internship, Albert Foundation
- William Zhu, May 2016- Summer Research Internship, Albert Foundation, Mentor for Independent Study Program (ISP)
- Kyle Higbee, June-Aug, 2017 Summer Research Internship, Albert Foundation
- Nicole E. Basler, June- Aug 2018, Summer Research Scholar, Albert Foundation
- Johnathan Cunha, June- Aug 2018, Summer Research Scholar, Albert Foundation
- John J McDermott, June- Aug 2019, Summer Research Scholar, Albert Foundation
- Rekha Narasimhan, June- Aug 2019, Summer Research Scholar, Albert Foundation

Graduate Students

- Jason Tchieu, MBI, Mentor and Doctoral thesis committee Chair, CAM Jamieson, 2004-2007
- Theresa Mendoza, MS program, Biology Master's Program Section of Cell and Developmental Biology, Division of Biological Sciences, UCSD, Thesis Advisor and Chair of Committee and Research Mentor, UCSD, July 2016 - Aug 2017.
- Jamillah Murtadha, MS program, Biology Master's Program Section of Cell and Developmental Biology, Division of Biological Sciences, UCSD, Thesis Advisor and Chair of Committee and Research Mentor, UCSD, July 2020 - Aug 2021.

Postdoctoral Fellows (PhD)

- Rika Miki, PhD 2003-2007
- Amy Strasner, PhD 2012- Aug 2015
- Sanghee Lee, PhD 2016, Nov1st, 2017- May 2021

Residents and Fellows (MD)

- Jason R. Woo, MD, 4th year Urology Resident (PGY4), Jan 2013-present.
- Michael Liss, MD, Urology Fellow, July 2012-July, 2014.
- Nishant Patel, MD, 4th Year Urology Resident (PGY4), July 2013-2016
- Elana Gobedu, MD, 4th Year Urology Resident (PGY4), Jan. 2014-2016
- Michelle McDonald, 4th Year Urology Resident (PGY4), Jan. 2014-June 2014
- Omer Raheem, MD, 4th Year Urology Resident (PGY4), July 2015-2016
- Unwanaobong Nseyo, PGY4, Urology, Jan 2015-present
- Marc Holden, MD, PGY4, July, 2016 - present
- Zachary Hamilton, MD SUO Urology Fellow, July, 2015-July, 2017
- Stephen Ryan, MD, SUO Fellow, July 2017 – July 2019
- Fady Gahlil, MD, Urology 4th year Resident, July 2019-July 2020

Visiting Scholars

- Omer Raheem, MD, Visiting Scholar, Ireland, Dec 2010-July, 2011.
- Young B. Jeong, MD, Visiting Scholar, South Korea, Dec 2010- Dec 2012.
- Fenghei Zhou, MD, Visiting Scholar, China 2010- Dec 2012
- Takeshi Hirata, MD, Visiting Scholar, Japan, April, 2013 –April 2014.
- Park Seung Chol, MD, Visiting Scholar, South Korea, August, 2013 – August 2014.
- Jin Seung Park, MD, Visiting Scholar, South Korea, Mar 2016 - Mar 2017
- Susan Logan, PhD, Visiting Scholar, New York University, NY, Mar 2017-Mar 2018
- Sung Ku Kang, MD, PhD, Visiting Scholar, South Korea, March 2019 – March 2020
- Hyun Tae Kim, MD, PhD, Visiting Scholar, South Korea, Aug 2019 – Aug 2020

High School Students

- Danielle Burner, High School Senior, UCSD Research Volunteer, Started as UCSD Freshman Fall 2014 continued as Research Volunteer then BISP199 Researcher in my lab from June 2013-2018, now MD/PhD student, Duke University, North Carolina, starting July 2020.
- Johnathan Hsu, High School Student, UCSD Research Volunteer, Fall 2017 to June 2019, now High School Senior.
- Rejina Roufegarinejad, High School Student, UCSD Research Volunteer, Summer 2019, now High School Senior.

Other Teaching Activities

Faculty participant, Urology Grand Rounds, UCLA Dept. of Urology weekly, 2002 - 2010
Leader, Jamieson Lab Journal Club, UCLA biweekly, 2003 - 2010

Faculty participant, Urology Grand Rounds, **UCSD** Department of Urology monthly, 2011 - present

Faculty participant, Surgery Grand Rounds, **UCSD** Department of Surgery, weekly, 2011 - present

Leader, Jamieson Lab Journal Club, **UCSD** Moores Cancer Center, weekly, 2011 – present

AFS Argentina undergrad science students (24 students), Lab tour and seminars on 2/13/14 and 2/28/14

Faculty Interviewer for Society of Urologic Oncology Fellowship candidate interviews UCSD, 2011-present

Faculty Interviewer for Urology Resident Candidate Interviews UCSD, 2012-present

Lecturer, Scripps Institute of Oceanography Course: SIO109 "Advanced Tools and Data Challenges for Bioinformatics", April29th 2019, May 29th, 2020

Discussion Leader, Bioengineering Design Group, Project #40: Bioinformatic Interpretation Of Copy Number Variation In Serial Metastasis Samples. Martin Galvan, Urvashi Kumar, Benjamin Pham, Hongru Yu, Mentor: Dr. Terry Gaasterland, Scripps Institute of Oceanography http://beweb.ucsd.edu/courses/senior-design/projects/

Outside of University of California

Lecturer, Course: Making and Using Microarrays, Cold Spring Harbor Laboratory, New York, Instructors: Joe DeRisi, Vishy Iyer, July, 2002

Science, Technology, Engineering, Arts and Medicine (STEAM) Discovery Day, Bird Rock Elementary School, Molecular biology presentation and led hands-on and interactive learning activity sessions DNA analysis.

Prostate Cancer Foundation (PCF) WNT Signaling Working Group, monthly presentations and meetings.

Prostate Cancer Foundation (PCF) Women in Science, Member, Annual Networking Symposium